Table 4_The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to trans

1,431 patients from four randomized controlled trials (CARES-005, EMERALD-1, LEAP-012, TALENTACE) were analyzed to compare combination therapy against standard treatment. Tonggang Zhou published this pooled analysis on figshare in May 2026 under a CC-BY-4.0 license. The results show a significant improvement in progression-free survival but no significant overall survival benefit, alongside increased adverse events.

Use Cases

• Compare progression-free survival outcomes based on hazard ratios reported in the analysis
• Analyze adverse event rates between treatment groups based on reported grade 3-4/serious event occurrences
• Evaluate tumor response rates using objective response rate data from RECIST and mRECIST criteria
• Assess treatment discontinuation reasons based on patient status at data cutoff

Strengths

• Data originates from four specific RCTs (CARES-005, EMERALD-1, LEAP-012, TALENTACE), providing a defined source
• Includes 1,431 patient records, offering a substantial sample size for analysis
• Analyzes multiple endpoints including OS, PFS, tumor response, and adverse events

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small (38.0 KB), suggesting limited scope or summary-level data

Provenance

Source

figshare

Collection Method

Pooled analysis of four randomized controlled trials identified via systematic search of six databases

Freshness

Last updated 2026-05-25 13:05:29; freshness should be verified